K
Kim A. Selting
Researcher at University of Illinois at Urbana–Champaign
Publications - 47
Citations - 1071
Kim A. Selting is an academic researcher from University of Illinois at Urbana–Champaign. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 15, co-authored 37 publications receiving 853 citations. Previous affiliations of Kim A. Selting include Colorado State University & University of Missouri.
Papers
More filters
Journal ArticleDOI
Response evaluation criteria for peripheral nodal lymphoma in dogs (v1.0)--a Veterinary Cooperative Oncology Group (VCOG) consensus document.
TL;DR: These guidelines are intended only for use in dogs, where peripheral lymphadenopathy represents the principal component of their disease and as such do not critically assess extranodal disease (e.g., primary cutaneous, central nervous system, gastrointestinal).
Journal ArticleDOI
Physical Properties of Nanoparticles That Result in Improved Cancer Targeting.
TL;DR: This review provides a summary of how the attributes of nanoparticles can be exploited to improve therapeutic efficacy and an ideal nanoparticle is proposed at the end of this review in order to guide future development of nanoparticle for improved drug targeting in vivo.
Journal ArticleDOI
Recent Trends in Feline Intestinal Neoplasia: an Epidemiologic Study of 1,129 Cases in the Veterinary Medical Database from 1964 to 2004
TL;DR: The most common intestinal tumor was lymphoma, but the most common nonlymphoid tumor was adenocarcinoma, and the Siamese breed and increasing age after 7 yr conferred an increased risk.
Journal ArticleDOI
Outcome of dogs with high-grade soft tissue sarcomas treated with and without adjuvant doxorubicin chemotherapy: 39 cases (1996-2004).
Kim A. Selting,Barbara E. Powers,Laura J. Thompson,Elise Mittleman,Elise Mittleman,Jeff W. Tyler,Mary H. Lafferty,Stephen J. Withrow +7 more
TL;DR: Adjuvant doxorubicin-based chemotherapy did not benefit this population of dogs with high-grade (grade 3) soft tissue sarcomas and outcome for visceral HGSTSs was similar to that of nonvisceral HGSTs in these cases.
Journal ArticleDOI
Gum arabic-coated radioactive gold nanoparticles cause no short-term local or systemic toxicity in the clinically relevant canine model of prostate cancer.
Sandra M. Axiak-Bechtel,Anandhi Upendran,Jimmy C. Lattimer,James Kelsey,Cathy S. Cutler,Kim A. Selting,Jeffrey N. Bryan,Carolyn J. Henry,Evan J. Boote,Deborah J. Tate,Margaret E. Bryan,Kattesh V. Katti,Raghuraman Kannan +12 more
TL;DR: GA-198AuNP therapy had no short-term toxicity in the treatment of prostatic cancer and localization of radioactivity within the prostate was lower than anticipated and likely due to normal vestigial prostatic ducts.